Vilazodone Hydrochloride Patent Expiration
Vilazodone Hydrochloride is Used for treating major depressive disorder (MDD). It was first introduced by Abbvie Inc
Vilazodone Hydrochloride Patents
Given below is the list of patents protecting Vilazodone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Viibryd |
US7834020 (Pediatric) | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec 05, 2022
(Expired) | Abbvie |
| Viibryd |
US8193195 (Pediatric) | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec 05, 2022
(Expired) | Abbvie |
| Viibryd |
US8236804 (Pediatric) | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec 05, 2022
(Expired) | Abbvie |
| Viibryd |
US8673921 (Pediatric) | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec 05, 2022
(Expired) | Abbvie |
| Viibryd | US7834020 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun 05, 2022
(Expired) | Abbvie |
| Viibryd | US8193195 | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun 05, 2022
(Expired) | Abbvie |
| Viibryd | US8236804 | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun 05, 2022
(Expired) | Abbvie |
| Viibryd | US8673921 | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun 05, 2022
(Expired) | Abbvie |
| Viibryd | US5532241 | Piperidines and piperazines |
Sep 29, 2014
(Expired) | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Vilazodone Hydrochloride's patents.
Latest Legal Activities on Vilazodone Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Vilazodone Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 08 Jul, 2024 | US8193195(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 25 Mar, 2024 | US8236804(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 22 Jan, 2024 | US8193195(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 04 May, 2022 | US7834020(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Sep, 2021 | US8673921(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jan, 2020 | US8236804(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Nov, 2019 | US8193195(Litigated) |
| Request for Trial Denied Critical
| 23 Jul, 2018 | US8673921(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 May, 2018 | US7834020(Litigated) |
| Petition Requesting Trial | 05 Jan, 2018 | US8673921(Litigated) |
Vilazodone Hydrochloride's Family Patents
